This conference is sponsored by the ITC Trial Lawyers Association, Philadelphia Intellectual Property Law Association, and New Jersey Intellectual Property Law Association and as a panel moderator, Aarti Shah will discuss:
- Available remedies.
- Do remedies apply to electronic transmissions? What about components used in electronic transmissions?
- The Commission has not yet decided whether exclusion of a biologic or biosimilar product would be against the public interest. However, a number of public interest issues were outlined by the Commission in Recombinant Factor VIII Products (Inv. No. 337-TA-956) before this investigation settled.
- Post remedy considerations.
Event Details
Tuesday, September 17, 2019
Kline Institute of Trial Advocacy
100-118 S 12th St, Philadelphia, Pennsylvania 19107
Speakers
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
